文献速递白血病

靶向间充质基质细胞可塑性以改变急性髓系白血病病程

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia.
PubMed 文献 · Blood · 2021-01-01

研究利用患者或健康供者来源的间充质基质细胞(MSC)与急性髓系白血病(AML)细胞构建三维人源化微环境,发现AML细胞通过物理连接重编程MSC转录组并损害其免疫调节功能,而缓解期MSC可恢复健康特征。CaV1.2通道阻滞剂乐卡地平与化疗联用可在体内外 impair 白血病进展。

要点

  • AML细胞与MSC形成物理连接,重编程其转录组并损害免疫调节功能。
  • 缓解期患者MSC在转录和功能层面恢复健康特征,包括分泌组。
  • 乐卡地平联合化疗在三维模型及体内可 impair 白血病进展。

核心结论

  • AML原始细胞改变骨髓微环境中MSC活性,促进疾病发生发展。
  • 靶向AML-MSC选择性CaV1.2通道阻滞剂乐卡地平联合化疗可 impair 白血病进展。

研究设计与样本

  • 构建包含AML细胞与患者来源或健康供者来源MSC的人源化三维微环境。
  • 在体外三维培养及体内植入模型中评估乐卡地平联合化疗的效果。

主要发现

  • AML细胞与MSC建立物理连接,介导重编程转录组,诱导异常增殖分化并严重损害MSC免疫调节能力。
  • 体外共培养时AML细胞调节健康MSC转录谱,使其功能类似AML-MSC,促进白血病进展。
  • 缓解期患者骨髓MSC在转录和功能水平恢复健康特征,包括分泌组。
  • 乐卡地平在三维体外及体内联合化疗时能够 impair 白血病进展。

临床怎么用

  • 考虑将MSC作为AML微环境治疗靶点,双靶向策略可能增强化疗效果。
  • 乐卡地平联合化疗或可成为AML治疗候选方案,需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Bone marrow (BM) microenvironment contributes to the regulation of normal hematopoiesis through a finely tuned balance of self-renewal and differentiation processes, cell-cell interaction, and secretion of cytokines that during leukemogenesis are altered and favor tumor cell growth. In pediatric acute myeloid leukemia (AML), chemotherapy is the standard of care, but >30% of patients still relapse. The need to accelerate the evaluation of innovative medicines prompted us to investigate the role of mesenchymal stromal cells (MSCs) in the leukemic niche to define its contribution to the mechanism of leukemia drug escape. We generated a humanized 3-dimensional (3D) niche with AML cells and MSCs derived from either patients (AML-MSCs) or healthy donors. We observed that AML cells establish physical connections with MSCs, mediating a reprogrammed transcriptome inducing aberrant cell proliferation and differentiation and severely compromising their immunomodulatory capability. We confirmed that AML cells modulate h-MSCs transcriptional profile promoting functions similar to the AML-MSCs when cocultured in vitro, thus facilitating leukemia progression. Conversely, MSCs derived from BM of patients at time of disease remission showed recovered healthy features at transcriptional and functional levels, including the secretome. We proved that AML blasts alter MSCs activities in the BM niche, favoring disease development and progression. We discovered that a novel AML-MSC selective CaV1.2 channel blocker drug, lercanidipine, is able to impair leukemia progression in 3D both in vitro and when implanted in vivo if used in combination with chemotherapy, supporting the hypothesis that synergistic effects can be obtained by dual targeting approaches.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Borella G, Da Ros A, Borile G, et al. Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia. Blood. 2021. PMID: 34010415. doi:10.1182/blood.2020009845

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。